Chen Y, Heiman M L
Division of Endocrinology, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 0545 46285, Indianapolis, IN, USA.
Regul Pept. 2000 Aug 25;92(1-3):113-9. doi: 10.1016/s0167-0115(00)00157-9.
Leptin is a hormone synthesized and secreted from adipose tissue. To study the physiologic effects of chronic leptin treatment, normal adult female Sprague-Dawley rats were injected subcutaneously for 35 days. Twice daily injections (250 microgram/day, b.i.d.) resulted in a significant (P<0.05) decrease in food intake that was maintained for 10 days before gradually returning to control level by day 21. Leptin decreased body weight by a maximum of 12% of the initial body weight on day 22 and remained reduced for the duration of the treatment. After 35 days of treatment, visible peritoneal adipose tissue was not detected. Body composition analysis showed that chronic injection of leptin resulted in a dramatic decrease in fat content (28+/-2 to 4+/-2 g, P<0.05; mean+/-SEM) while the lean content remained unchanged. Rats pair-fed to the leptin-treated group but treated with vehicle had the same body composition (23+/-3 g fat mass) as that measured for the ad libitum fed controls. Using indirect calorimetry we observed that leptin decreased respiratory quotient and thus increased fat oxidation. Leptin also prevented energy expenditure reduction typically associated with food restriction. Leptin treatment for 35 days decreased plasma triglyceride (0.75+/-0.07 to 0.30+/-0.03 mM, P<0.05), free fatty acid (0.56+/-0.06 to 0.32+/-0.04 mM) and insulin (3.2+/-0.5 to 1. 4+/-0.4 ng/ml, P<0.05) concentrations despite the fact that food intake was normalized by day 35. Withdrawal of leptin triggered hyperphagia indicating that leptin biology remained throughout the duration of the chronic treatment. These data suggest that leptin reduces fat mass by initially decreasing appetite and by maintaining enhanced fat utilization even when food intake has returned to that of vehicle-treated control.
瘦素是一种由脂肪组织合成并分泌的激素。为了研究长期注射瘦素的生理效应,对成年雌性正常斯普拉格-道利大鼠进行皮下注射,持续35天。每日注射两次(250微克/天,一日两次)导致食物摄入量显著减少(P<0.05),这种减少持续了10天,到第21天逐渐恢复到对照水平。在第22天,瘦素使体重最多降低了初始体重的12%,并且在整个治疗期间体重一直维持在较低水平。治疗35天后,未检测到可见的腹膜脂肪组织。身体成分分析表明,长期注射瘦素导致脂肪含量显著降低(从28±2克降至4±2克,P<0.05;均值±标准误),而瘦肉含量保持不变。与注射瘦素组配对喂食但注射赋形剂的大鼠,其身体成分(脂肪量23±3克)与自由采食对照组相同。通过间接测热法,我们观察到瘦素降低了呼吸商,从而增加了脂肪氧化。瘦素还防止了通常与食物限制相关的能量消耗减少。瘦素治疗35天降低了血浆甘油三酯(从0.75±0.07毫摩尔降至0.30±0.03毫摩尔,P<0.05)、游离脂肪酸(从0.56±0.06毫摩尔降至0.32±0.04毫摩尔)和胰岛素(从3.2±0.5纳克/毫升降至1.4±0.4纳克/毫升,P<0.05)的浓度,尽管到第35天食物摄入量已恢复正常。停止注射瘦素引发了食欲亢进,这表明在整个长期治疗期间瘦素的生物学作用一直存在。这些数据表明,瘦素最初通过降低食欲,即使在食物摄入量已恢复到注射赋形剂对照组水平时,仍通过维持增强的脂肪利用来减少脂肪量。